MOLECULAR BREAST CANCER THERAPY AND CARCINOGENESIS

分子乳腺癌治疗和致癌作用

• 批准号: 3568333
• 负责人: JAMES H DOROSHOW
• 金额: $ 39.99万
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 1998-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3568333
• 关键词: autologous transplantation; bone marrow transplantation; breast neoplasm /cancer diagnosis; breast neoplasms; carcinoembryonal antigen; carcinogenesis; clinical trials; drug resistance; female; gene therapy; health care service planning; health science research support; human subject; human therapy evaluation; molecular oncology; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; patient /disease registry

The principal goal of this proposal is to develop a cohesive, multidisciplinary breast cancer program at the City of Hope Cancer Research Center (COH). From 1985 to 1992 (the last calendar year for which definitive data are available), the breast cancer population increased from 15 to 25% of the entire cancer patient population at COH; in absolute terms, this represented an increase from 242 to 478 new breast cancer patients evaluated per year. Patients with breast cancer now embody the single most common diagnosis treated at our institution. This increase in patient volume has been accompanied by a remarkable increase in the extent of breast cancer-related clinical and laboratory research at the COH. Thus, it is appropriate to propose to develop the infrastructure to support a new Cancer Center program that will focus on interactive, investigative basic, clinical, and cancer control initiatives in breast cancer. The goals of the developing COH Breast Cancer Research Program are: (1) to complete innovative clinical trials in patients with breast cancer in the areas of gene therapy, radioimmunotherapy, high-dose chemotherapy with autologous peripheral blood progenitor cell rescue, biochemical modulation, and drug resistance reversal; (2) to perform pre-clinical studies of novel gene delivery systems and gene-directed breast cancer therapies, new monoclonal antibodies against the carcinoembryonic antigen as well as other breast cancer antigens, and the molecular pharmacology of breast cancer drug resistance aimed at the continuing development of new therapeutic agents for this disease; and (3) to investigate the molecular events leading to breast carcinogenesis and improve the diagnosis and control of breast cancer. Based on the availability of a large patient resource, a proven track record of accrual to complex, innovative institutional breast cancer clinical trials, and a strong history of productive basic and clinical research interactions in molecular pharmacology, molecular immunology, tumor biology, virology, and cancer control that have been applied directly to enhance the therapeutic outcome for patients with breast cancer, we propose to unify breast cancer research at the City of Hope. The growth and maturation of the COH Breast Cancer Research Program will focus the interests and facilitate the development of a strongly interactive research team with the potential to make an important contribution to the reduction of breast cancer incidence and mortality.

这项建议的主要目标是建立一个有凝聚力的， 希望之城癌症研究中心的多学科乳腺癌项目 中心（COH）。1985年至1992年（ 明确的数据是可用的），乳腺癌人口从 COH的整个癌症患者人群的15%至25%;绝对值 这意味着从242例增加到478例新发乳腺癌 每年评估的患者。乳腺癌患者现在体现了 我们机构治疗的最常见的一种诊断。的这种增加 患者数量的增加伴随着 乳腺癌相关的临床和实验室研究在COH。因此，在本发明中， 建议发展基础设施以支持新的 癌症中心计划，将侧重于互动，调查基本， 乳腺癌的临床和癌症控制倡议。的目标 发展COH乳腺癌研究计划是：（1）完成 在乳腺癌患者中进行的创新临床试验， 基因治疗，放射免疫治疗，自体大剂量化疗， 外周血祖细胞拯救、生化调节和药物 耐药逆转;（2）进行新基因的临床前研究 递送系统和基因导向的乳腺癌疗法，新的单克隆 抗癌胚抗原以及其他乳腺癌的抗体 癌抗原和乳腺癌药物的分子药理学 针对新治疗剂的持续开发的耐药性 （3）研究导致这种疾病的分子事件， 提高乳腺癌的诊断和控制 癌基于大量患者资源的可用性， 复杂的、创新的机构性乳腺癌的累积记录 临床试验，以及生产基础和临床的强大历史 研究分子药理学、分子免疫学、 肿瘤生物学、病毒学和癌症控制， 为了提高乳腺癌患者的治疗效果，我们 提议在希望之城统一乳腺癌研究。 生长 和COH乳腺癌研究计划的成熟将集中在 兴趣和促进发展的强烈互动的研究 有潜力为减少排放做出重要贡献的团队 乳腺癌的发病率和死亡率。